Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mar Drugs
2019 Jun 08;176:. doi: 10.3390/md17060342.
Show Gene links
Show Anatomy links
DSPE-PEG Modification of α-Conotoxin TxID.
Zhao W
,
Xiong Y
,
Zhangsun D
,
Luo S
.
???displayArticle.abstract???
In order to improve stability of a peptide marine drug lead, α-conotoxin TxID, we synthesized and modified TxID at the N-terminal with DSPE-PEG-NHS by a nucleophilic substitution reaction to prepare the DSPE-PEG-TxID for the first time. The reaction conditions, including solvent, ratio, pH, and reaction time, were optimized systematically and the optimal one was reacted in dimethyl formamide at pH 8.2 with triethylamine at room temperature for 120 h. The in vitro stabilities in serum, simulated gastric juice, and intestinal fluid were tested, and improved dramatically compared with TxID. The PEG-modified peptide was functionally tested on α3β4 nicotinic acetylcholine receptor (nAChR) heterologously expressed in Xenopus laevis oocytes. The DSPE-PEG-TxID showed an obvious inhibition effect on α3β4 nAChR. All in all, the PEG modification of TxID was improved in stability, resistance to enzymatic degradation, and may prolong the half-life in vivo, which may pave the way for the future application in smoking cessation and drug rehabilitation, as well as small cell lung cancer.
Figure 1. (A) Sequence and disulfide bond connection of TxID, # represents a C-terminal amide; (B) RP-UPLC chromatogram of TxID; (C) ESI-MS data of TxID.
Figure 2. (A) Synthesis scheme of DSPE-PEG-TxID; (B) MADLI-TOF spectrum of DSPE-PEG-TxID; (C) MADLI-TOF spectrum of DSPE-PEG-NHS.
Figure 3. Chromatograms of reaction optimization under various conditions, the changes in solvent (A), ratio of polypeptide to PEG (B), pH (C) and reaction time (D) (see Table 2).
Figure 4. α-Conotoxin TxID and DSPE-PEG-TxID were tested on neuronal rat α3β4 nAChR subtype expressed in Xenopus laevis oocytes. The representative current traces showing the inhibition of rat α3β4 ACh-evoked currents by TxID (A) and DSPE-PEG-TxID (B).
Figure 5. Stability of TxID and DSPE-PEG-TxID in serum (A), simulated gastric fluid (SGF) (B), and simulated intestinal fluid (SIF) (C). * p < 0.05, ** p < 0.01, *** p < 0.001, compared with the TxID.
Albuquerque,
Mammalian nicotinic acetylcholine receptors: from structure to function.
2009, Pubmed
Albuquerque,
Mammalian nicotinic acetylcholine receptors: from structure to function.
2009,
Pubmed
Azam,
Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors.
2009,
Pubmed
Bailon,
PEG-modified biopharmaceuticals.
2009,
Pubmed
Cai,
Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy.
2014,
Pubmed
Clark,
The engineering of an orally active conotoxin for the treatment of neuropathic pain.
2010,
Pubmed
Dai,
The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus.
2003,
Pubmed
Di Cesare Mannelli,
α-conotoxin RgIA protects against the development of nerve injury-induced chronic pain and prevents both neuronal and glial derangement.
2014,
Pubmed
Fishburn,
The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.
2008,
Pubmed
Gotti,
Neuronal nicotinic receptors: from structure to pathology.
2004,
Pubmed
Hurst,
Nicotinic acetylcholine receptors: from basic science to therapeutics.
2013,
Pubmed
Improgo,
Nicotinic acetylcholine receptors mediate lung cancer growth.
2013,
Pubmed
Kompella,
Alanine scan of α-conotoxin RegIIA reveals a selective α3β4 nicotinic acetylcholine receptor antagonist.
2015,
Pubmed
,
Xenbase
Luo,
A novel inhibitor of α9α10 nicotinic acetylcholine receptors from Conus vexillum delineates a new conotoxin superfamily.
2013,
Pubmed
Luo,
Characterization of a novel α-conotoxin TxID from Conus textile that potently blocks rat α3β4 nicotinic acetylcholine receptors.
2013,
Pubmed
,
Xenbase
Luo,
A novel α4/7-conotoxin LvIA from Conus lividus that selectively blocks α3β2 vs. α6/α3β2β3 nicotinic acetylcholine receptors.
2014,
Pubmed
,
Xenbase
Luo,
Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist.
2015,
Pubmed
,
Xenbase
Maddux,
Multidimensional methods for the formulation of biopharmaceuticals and vaccines.
2011,
Pubmed
Mei,
The use of α-conotoxin ImI to actualize the targeted delivery of paclitaxel micelles to α7 nAChR-overexpressing breast cancer.
2015,
Pubmed
Mross,
First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors.
2013,
Pubmed
Napier,
Intrathecal α-conotoxins Vc1.1, AuIB and MII acting on distinct nicotinic receptor subtypes reverse signs of neuropathic pain.
2012,
Pubmed
Olivera,
Subtype-selective conopeptides targeted to nicotinic receptors: Concerted discovery and biomedical applications.
2008,
Pubmed
Pan,
Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL).
2013,
Pubmed
Pasut,
State of the art in PEGylation: the great versatility achieved after forty years of research.
2012,
Pubmed
Robinson,
Conotoxin gene superfamilies.
2014,
Pubmed
Sanchez-Ruiz,
Protein kinetic stability.
2010,
Pubmed
Tamizi,
Forced degradation studies of biopharmaceuticals: Selection of stress conditions.
2016,
Pubmed
Tang,
Pharmacokinetic aspects of biotechnology products.
2004,
Pubmed
Tong,
Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles.
2012,
Pubmed
Wang,
Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs.
2015,
Pubmed
Wu,
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery.
2013,
Pubmed
Zhangsun,
Key residues in the nicotinic acetylcholine receptor β2 subunit contribute to α-conotoxin LvIA binding.
2015,
Pubmed
,
Xenbase
Zündorf,
PEGylation--a well-proven strategy for the improvement of recombinant drugs.
2014,
Pubmed
